Neuropeptide Y-based recombinant peptides ameliorate bone loss in mice by regulating hematopoietic stem/progenitor cell mobilization
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Ovariectomy-induced bone loss is related to an increased deposition of osteoclasts on bone surfaces. We reported that the 36-amino-acid-long neuropeptide Y (NPY) could mobilize hematopoietic stem/progenitor cells (HSPCs) from the bone marrow to the peripheral blood by regulating HSPC maintenance factors and that mobilization of HSPCs ameliorated low bone density in an ovariectomy-induced osteoporosis mouse model by reducing the number of osteoclasts. Here, we demonstrated that new NPY peptides, recombined from the cleavage of the full-length NPY, showed better functionality for HSPC mobilization than the full-length peptide. These recombinant peptides mediated HSPC mobilization with greater efficiency by decreasing HSPC maintenance factors. Furthermore, treatment with these peptides reduced the number of osteoclasts and relieved ovariectomy-induced bone loss in mice more effectively than treatment with full-length NPY. Therefore, these results suggest that peptides recombined from full-length NPY can be used to treat osteoporosis.
Abstract
Ovariectomy-induced bone loss is related to an increased deposition of osteoclasts on bone surfaces. We reported that the 36-amino-acid-long neuropeptide Y (NPY) could mobilize hematopoietic stem/progenitor cells (HSPCs) from the bone marrow to the peripheral blood by regulating HSPC maintenance factors and that mobilization of HSPCs ameliorated low bone density in an ovariectomy-induced osteoporosis mouse model by reducing the number of osteoclasts. Here, we demonstrated that new NPY peptides, recombined from the cleavage of the full-length NPY, showed better functionality for HSPC mobilization than the full-length peptide. These recombinant peptides mediated HSPC mobilization with greater efficiency by decreasing HSPC maintenance factors. Furthermore, treatment with these peptides reduced the number of osteoclasts and relieved ovariectomy-induced bone loss in mice more effectively than treatment with full-length NPY. Therefore, these results suggest that peptides recombined from full-length NPY can be used to treat osteoporosis.
참고문헌 (25)
- van den Bergh JP, "Osteoporosis, frailty and fracture: implications for case finding and therapy", Nat Rev Rheumatol, 8, pp.163~172 (2012)
- Manolagas SC, "Sex Steroids and Bone", Endocr Rev, 21, pp.115~137 (2000)
- NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and therapy, "Osteoporosis prevention, diagnosis, and therapy", JAMA, 285, pp.785~795 (2001)
- Kim TH, "The effects of luteolin on osteoclast differentiation, functionin vitro and ovariectomy-induced bone loss", J Nutr Biochem, 22, pp.8~15 (2011)
- Kim T, "The anti-osteoporotic effect of Yijung-tang in an ovariectomized rat model mediated by inhibition of osteoclast differentiation", J Ethnopharmacol, 146, pp.83~89 (2013)
- Takayanagi H, "Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems", Nat Rev Immunol, 7, pp.292~304 (2007)
- Ding L, "Endothelial and perivascular cells maintain haematopoietic stem cells", Nature, 481, pp.457~462 (2012)
- Butler JM, "Endothelial cells are essential for the self-renewal and repopulation of Notch-dependent hematopoietic stem cells", Cell Stem Cell, 6, pp.251~264 (2010)
- Lévesque JP, "The endosteal ‘osteoblastic’ niche and its role in hematopoietic stem cell homing and mobilization", Leukemia, 24, pp.1979~1992 (2010)
- Arai F, "Tie2", angiopoietin-1 signaling regulates hematopoietic stem cells quiescence in the bone marrow niche, 2004, pp.118, 149~161
- Sugiyama T, "Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches", Immunity, 25, pp.977~988 (2006)
- Tanaka Y, "Osteoblasts are regulated by the cellular adhesion through ICAM-1 and VCAM-1", J Bone Miner Res, 10, pp.1462~1469 (1995)
- Jung Y, "Regulation of SDF-1 (CXCL12) production by osteoblasts; a possible mechanism for stem cell homing", Bone, 38, pp.497~508 (2006)
- Méndez-Ferrer S, "Mesenchymal and haematopoietic stem cells form a unique bone marrow niche", Nature, 466, pp.829~834 (2010)
- Katayama Y, "Signals from the sympathetic nervous system regulate hematopoietic stem cell egress from bone marrow", Cell, 124, pp.407~421 (2006)
- 임진영, "AMD3100 improves ovariectomy-induced osteoporosis in mice by facilitating mobilization of hematopoietic stem", progenitor cells, 2014, pp.47(8), 439~444[DOI]
- Ishii M, "Sphingosine-1- phosphate mobilizes osteoclast precursors and regulates bone homeostasis", Nature, 458, pp.524~528 (2009)
- Zukowska-Grojec Z, "Neuropeptide Y. A novel sympathetic stress hormone and more", Ann NY Acad Sci, 771, pp.219~233 (1995)
- Kalra SP, "NPY and cohorts in regulation appetite, obesity and metabolic syndrome: beneficial effects of gene therapy", Neuropeptides, 38, pp.201~211 (2004)
- Kuo LE, "Neuropeptide Y acts directly in the periphery on fat tissue and mediates stress-induced obesity and metabolic syndrome", Nat Med, 13, pp.803~811 (2007)
- Park MH, "Neuropeptide Y regulates the hematopoietic stem cell microenvironment and prevents nerve injury in the bone marrow", EMBO J, 34, pp.1648~1660 (2015)
- Park MH, "Neuropeptide Y Induces Hematopoietic Stem", Progenitor Cell Mobilization by Regulating Matrix Metalloproteinase-9 Activity Through Y1 Receptor in Osteoblasts, 2016, pp.34, 2145~2156
- Rose JB, "Neuropeptide Y fragments derived from neprilysin processing are neuroprotective in a transgenic model of Alzheimer's disease", J Neurosci, 29, pp.1115~1125 (2009)
- Ehninger A, "The bone marrow stem cell niche grows up: mesenchymal stem cells and macrophages move in", J Exp Med, 208, pp.421~428 (2011)
- Bae JS, "Neurodegeneration augments the ability of bone marrow-derived mesenchymal stem cells to fuse with Purkinje neurons in Niemann-Pick type C mice", Hum Gene Ther, 16, pp.1006~1011 (2005)